Patients & Caregivers
Cancer Research Institute CEO Explains Immunotherapy in Rare Cancers
Jill O'Donnell-Tormey, PhD, discusses immunotherapy and the immune system's role in rare cancers.
Ignyta Chairman and CEO: Entrectinib Has A Really Good Shot
Rare Disease Report
recently spoke with Jonathan Lim, M.D., the Chairman and CEO of Ignyta about the exciting results and next steps for Entrectinib.
Rare Lung Cancer Drug Approved by FDA
The FDA announced the granting of regular approval to Alecensa (alectinib) for anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).
FDA Grants Approval to Zelboraf for Certain Patients with Rare Blood Disease
Today, it was announced that Zelboraf received expanded approval for the drug to include the treatment of adult patients with Erdheim-Chester disease whose cancer cells have the BRAF V600 mutation.
FDA Issues Warning Letters to 4 Companies Claiming Their Cannabidiol Product Can Treat Cancer
The companies are: Greenroads Health, Natural Alchemist, That's Natural!, Stanley Brothers
Accelerated Approval Granted to Mantle Cell Lymphoma Treatment
Accelerated approval was granted today by the FDA to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma.
Therapy for Heregulin Positive Lung Cancer Gets Orphan Drug Designation
This morning, Merrimack announced that orphan drug designation was granted to MM-121 (seribantumab) by the U.S. Food and Drug Administration (FDA).
Combination Therapy Shows Encouraging Results in Patients with Clear Cell Renal Cell Carcinoma
Updated results from an ongoing Phase 1/2 study of X4P-001-IO in combination with Inlyta to treat patients with clear cell renal cell carcinoma were announced.
Is Y-90 Resin Microspheres Better or Worse Than Sorafenib for Treating Liver Cancer?
The large phase 3 study observed that efficacy was the same for both treatments.
Steven Benner of Astellas Discusses New Gilteritinib Designation
Rare Disease Report
spoke with Steven Benner, MD about the new designation, the development program, and the functionality and target for the potential therapy.
<< Prev Page
Next Page >>
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.